Here is what was said in that link that Prestonian posted. NVGN Soars, NYMX, PPHM Progress, ISIS Pockets Payment, THRX Gets A Date With FDA
Novogen Ltd. ( NVGN ) surged as much as 263% to $7.60 in regular trading on Tuesday after the company announced that its lead experimental drug, CS-6, has proven to be highly active against ovarian cancer stem cells in laboratory studies.
Cancer stem cells have been identified in a range of cancers including gut, skin, ovarian and brain cancers and leukaemia. Being almost completely resistant to radiotherapy and standard anti-cancer drugs, the cancer stem cells are thought to be the cause of cancer relapse.
Graham Kelly, Novogen CEO said, "it is important to point out that this is early days and we have some way to go before we will have clinical evidence, but there is no doubt that this news elevates CS-6 and the super-benzopyran family of drugs to which it belongs into an entirely new clinical dimension where we hope it will be possible to provide a comprehensive cancer treatment."
Wall St. Cheat Sheet Will Novogen’s Positive Drug Results Attract These Top Institutional Shareholders? By Deann Marin | More Articles February 19, 2013
Novogen Limited (NASDAQ:NVGN) shares that are trading in Australia saw an increase surpassing 300% after new data revealed that a drug they are developing has proven to be highly effective in ceasing the growth of ovarian cancer stem cells, Proactive Investors Australia reports. Novogen shares listed in New York saw a rise of more than 120% to $4.69 in early trade.
Will Novogen Limited’s shareholder’s increase their holdings? They reported owning a total of 213,421 shares on 12/31/2012. The shares closed at $2.29 on 12/31/2012.
Here are the ten largest positions in Novogen Limited at the end of December 31st, 2012.
Jefferies Group Inc. /DE/ held 111,854 shares on 12/31/2012 worth $777,385. This brought the portfolio total to 0.01%.
Renaissance Technologies LLC. held 48,940 shares on 12/31/2012 worth $340,133. This brought the portfolio total to 0.0%.
Gilman Hill Asset Management LLC. held 23,471 shares on 12/31/2012 worth $163,123. This brought the portfolio total to 0.13%.
Muhlenkamp & Co. Inc. held 18,184 shares on 12/31/2012 worth $126,379. This brought the portfolio total to 0.03%.
First New York Securities LLC. /NY held 5,200 shares on 12/31/2012 worth $36,140. This brought the portfolio total to 0.01%.
Bank of America Corp. /DE/ held 4,666 shares on 12/31/2012 worth $32,429. This brought the portfolio total to 0.0%.
UBS AG held 896 shares on 12/31/2012 worth $6,227. This brought the portfolio total to 0.0%.
Creative Planning held 200 shares on 12/31/2012 worth $1,390. This brought the portfolio total to 0.0%.
Ameriprise Financial Inc. held 10 shares on 12/31/2012 worth $69. This brought the portfolio total to 0.0%.
Knight Capital Group Inc. held 0 shares on 12/31/2012 worth $0. This brought the portfolio total to %.
